Document is current
Any future updates will be listed below
-
Authors
Polimanti, Renato https://orcid.org/0000-0003-0745-6046
Wendt, Frank R. https://orcid.org/0000-0002-2108-6822
Pathak, Gita A.
Tylee, Daniel S. https://orcid.org/0000-0002-7579-6096
Tcheandjieu, Catherine
Hilliard, Austin T.
Levey, Daniel F. https://orcid.org/0000-0001-8431-9569
Adhikari, Keyrun
Gaziano, J. Michael
O’Donnell, Christopher J. https://orcid.org/0000-0002-2667-8624
Assimes, Themistocles L.
Stein, Murray B. https://orcid.org/0000-0001-9564-2871
Gelernter, Joel https://orcid.org/0000-0002-4067-1859
-
Funding
Funding for this research was provided by:
U.S. Department of Veterans Affairs
- License Information
-
More Information
Article History
Received: 16 March 2022
Revised: 29 July 2022
Accepted: 5 August 2022
First Online: 19 August 2022
Competing interests
: RP received a research grant from Alkermes. RP and JG received personal fees from Karger Publishers for their editorial work for Complex Psychiatry. JG is named as co-inventor on Patent Cooperation Treaty application no. 15/878,640 titled ‘Genotype-guided dosing of opioid agonists’, filed on January 24, 2018. CJO. received payment for editorial work for UpToDate and JAMA Cardiology and is currently employed by Novartis Institute of Biomedical Research. MBS received consulting fees from Acadia Pharmaceuticals, Aptinyx, Bionomics, Boehringer Ingelheim, Clexio Biosciences, EmpowerPharm, Engrail Therapeutics, Epivario, GW Pharmaceuticals, Janssen, and Jazz Pharmaceuticals; and payment for editorial work for UpToDate and the journals Biological Psychiatry and Depression and Anxiety. The other authors declare no competing financial interests.
